April 1, 2026: More People Join Federal Litigation Over Side Effects from Zepbound and Other GLP-1 Drugs As of April 1, 2026, there are 3,546 pending claims in MDL 3094 ( IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation )
Clinical Response Assessment Doctor checks are also important to see if B12 shots are working
The primary mechanism of action involves binding to GLP-1 receptors on pancreatic beta cells, which enhances glucose-dependent insulin secretion and suppresses inappropriate glucagon release
ChemistrySelect 10 (e202404147)
Potential Risks: Conversely, other studies indicate that GLP-1 receptor agonists might increase the risk of developing colorectal cancer
Diarrhea may occur in up to 10% of individuals when starting the product, so it is advised to gradually introduce it